CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee

CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company based in China, has announced that it will continue the Phase 2 trial of CAN008 in patients with glioblastoma multiforme (GBM) in China. This decision is based on the interim analysis recommendation of the independent data monitoring committee. The ongoing Phase 2 study aims to evaluate the efficacy and safety of CAN00..